Novo Nordisk’s semaglutide (Wegovy) delivered impressive results against liver fibrosis and MASH (metabolic dysfunction-associated steatohepatitis) in a phase III trial, the company has reported. The trial showed a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening…

When compared to seven other anti-diabetic drugs, semaglutide may significantly lower the risk of Alzheimer’s disease in people with type 2 diabetes, according to new research from the Case Western Reserve School of Medicine. These results, which were based on data from a national health records database, were consistent across…

While semaglutide has been in the biopharma limelight for its impressive effects on weight loss in adults with and without type 2 diabetes, it looks like it could soon be playing second fiddle to another glucagon-like peptide 1 GLP-1 receptor agonist-based medication when it comes to weight loss. A study…

Harith Rajagopalan, MD, PhD, founded Fractyl Health with the vision of eliminating obesity, and it looks like his idea for how to do that has gained some preclinical steam. The metabolic therapeutics company has new data from Rejuva—its adeno-associated virus (AAV)-based glucagon-like peptide-1 (GLP-1) pancreatic gene therapy program designed to…

New research from a Phase IIb pilot study has found that a weekly injection of semaglutide (Wegovy) reduced the amount of fat in the liver by 31% in people infected with HIV who have metabolic dysfunction-associated steatotic liver disease (MASLD). The regimen was also well tolerated noted the researchers who…

Novo Nordisk today announced it has notched another win for its GLP-1 agonist semaglutide (Ozempic), this time for reducing cardiovascular disease and slowing kidney disease in diabetic patients. The latest results from the FLOW trial suggest the drug cuts risk of death in this population by as much as 24%.  …

A new study has identified two distinct subtypes of metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as nonalcoholic fatty liver disease (NAFLD)—a fatty liver disease that can progress to cirrhosis, liver cancer, and other health complications. The disease spans from benign fat accumulation in the liver (steatosis) to its more…

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular disease shows these drugs have significant benefits in people with and without diabetes. In both types of patients, the combined reduction in the risk of kidney failure, worsening kidney function, and death due to…

Many people have tried dietary changes, lifestyle interventions, medications, and bariatric surgery, and other methods for managing their obesity. While they may help in the short term, the “obesogenic” metabolic memory causes many of them to put the weight back on. A recent study in Nature suggests that the epigenome…

In a preliminary study set to be presented at the American Heart Association’s Scientific Sessions 2024, a team of researchers from the Mayo Clinic in Rochester, Minnesota, found that GLP-1 receptor agonists and SGLT2 inhibitors may significantly reduce the risk of heart attacks, second strokes, and death in adults who…

Phenomix Sciences, a biotech focusing on obesity phenotyping and biomarker testing, will partner with genetic testing and counseling provider InformedDNA to provide targeted obesity treatment based on underlying biology. Obesity is a very heterogeneous condition that can manifest for many different reasons. The approval of Novo Nordisk’s GLP-1 agonist Wegovy (semaglutide) for…

Four years ago, Sendhil Mullainathan, Ziad Obermeyer, Niyum Gandhi, and Elliott Green began their quest to solve what they believe is the true bottleneck of using AI in healthcare—real-world data. “[Mullainathan and Obermeyer] had written a pivotal paper on AI and healthcare that focused on the inability of AI to…

A recent Cleveland Clinic study has shed light on the critical factors influencing long-term weight loss in patients with obesity prescribed GLP-1 receptor agonist (RA) medications like semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda, Victoza). These drugs, widely used to lower blood sugar and promote weight loss in individuals with type…

There is a team readily available to report 24/7 to a facility at the University of Chicago Medical Center to quickly receive and process a deceased donor’s pancreas into isolated islets for infusion into a patient with type 1 diabetes. The results have been astounding. Some patients who underwent allogeneic…

Possibly adding a new entrant to the highly competitive diabetes/weight loss market, Roche has announced positive interim results from an ongoing Phase I trial for its oral small molecule GLP-1 receptor agonist, CT996. The drug is being developed for both type 2 diabetes and obesity, and the company says treatment…